The results
AMBAR, an innovative treatment approach for Alzheimer's disease (AD) based on the combination of regular Plasmapheresis with albumin and immunoglobulin infusions under development in phase IIb/III, may offer a new treatment pathway for the illness in the future.
Primary outcomes of AMBAR trial have demonstrated a significant reduction in the progression of Alzheimer's in moderate patients.
The results presented at the 14th International Congress of Alzheimer's and Parkinson's (AD/PD) in Lisbon (Portugal) complement and confirm these primary outcomes, not only for patients with moderate-phase Alzheimer's disease, but also for patients in the mild phase of the disease.
The additional results presented at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA) are in line with the ones presented previously and show positive effects on the three most important endpoints in Alzheimer's disease trials.
CSL has more upside..., page-6
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.39 |
Change
-4.360(1.45%) |
Mkt cap ! $143.3B | |||
| Open | High | Low | Value | Volume |
| $299.64 | $300.03 | $294.81 | $108.5M | 364.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 42 | $295.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $295.39 | 14 | 5 |
View Market Depth
| Last trade - 15.52pm 08/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |